

ASX Release
12 October 2017

RHS wins HWA Lab competition

Highlights

- RHS takes out first prize in the inaugural HWA Lab competition
- Provides RHS with additional funding to advance software development to accompany DOPlify™
- RHS presenting at key National and International reproductive medicine meetings

Adelaide, 12 October 2017: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the Company has been awarded first prize in the inaugural HWA Lab pitching competition.

The inaugural Hybrid World Adelaide (“HWA”) conference was held on 4-5 October bringing together digital experts across space, biotech, gaming, automation, robotics, blockchain, cybersecurity, agritech and artificial intelligence. The conference was followed by the HWA Lab program designed to identify and fund the next generation of applied digital technologies. The opportunity to pitch was open to South Australian, interstate and overseas companies and RHS was awarded the first prize of \$25,000 from the total prize pool of \$85,000 funded through TechInSA.

RHS was one of 15 companies selected to pitch for the grant funding aimed at bringing new projects, products or concepts using digital technologies to solve real world problems. RHS will use these funds to develop improvements in Next Generation Sequencing data analysis that are particularly suited to the Company’s own DOPlify™ Whole Genome Amplification kit. Applications include genetic profiling of circulating tumour cells, which will assist in characterising the cause and location of the primary tumour to potentially further personalised medical treatments. In addition, non-invasive combined Pre-implantation Genetic Screening and Diagnosis of IVF embryos using spent embryo culture medium will be assisted. Being connected to GigCity and now having access to funding for software improvements positions RHS to use its experience and expertise to advance single cell applications using its world class DOPlify™ kit.

RHS looks forward to further updating the market during the coming weeks with upcoming presentations and exhibitions at the Fertility Society of Australia meeting on 15-18 October in Adelaide and the American Society for Reproductive Medicine meeting on 30 October to 2 November in San Antonio, Texas. These commercially important conferences will also see the **release of data on non-invasive PGS using spent embryo culture media developed together with Repromed**, part of the Monash IVF Group.

Application of DOPlify™ in cancer

There are over 14 million new cancer diagnoses each year and over 8 million deaths worldwide. The outcomes of treatment are far more positive when cancer is detected at the earliest stages than at late stage. For example, the 5 year survival rate for stage 1 lung cancer is 52% but by stage 4 it has dropped to 4%. Cancer genetic tests need the equivalent of more than 8,000 cells worth of tumour DNA. With 1-10 circulating tumour cells per ml of patient blood, there would need to be almost a litre of blood taken to retrieve enough tumour cells. DOPlify™ amplifies the DNA from a single cell turning it into the equivalent of 200,000 cells of DNA, meaning that these downstream genetic tests can be applied to single cells. RHS also has patented the ability to increase the copies of clinically relevant regions such as oncogenes to create millions of copies of the most informative areas, further improving the sensitivity of testing whilst keeping the cost of analysis low.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9348
michelle.fraser@rhsc.com.au

Dr David Brookes
Chairman
Tel: (+61 8) 8152 9383
david.brookes@rhsc.com.au

About RHS

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes, with deep technical experience in the field. DOPlify™ is a platform product for whole genome amplification (WGA) of single or small numbers of cells. DOPlify™ is applicable to the global Next Generation Sequencing (NGS) market.

RHS Ltd.

ACN 010 126 708
ASX: RHS

Issued Capital

89.9 million shares
7.05 million options

Registered Office

Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors

Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Dr Michelle Fraser (CEO)

Finance Officer

& Company Secretary
Raymond Ridge